"CORONAVIRUS INFO: Penn Medicine is dedicated to the health and safety of patients, their families, and our staff. Please visit our website for COVID-19 updates, including coronavirus FAQs, our visitation policy, and drive-thru testing."

During the past decade, Abramson Cancer Center of the University of Pennsylvania conducted 368 clinical trials. In the 10-year time frame, 368 clinical trials started and 236 clinical trials were completed, i.e. on average, 64.1% percent of trials that started reached the finish line to date. In the past 5 years, 122 clinical trials started and 149 clinical trials were completed. i.e. 122.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Abramson Cancer Center of the University of Pennsylvania" #1 sponsor was "Abramson Cancer Center at Penn Medicine" with 270 trials, followed by "National Cancer Institute (NCI)" with 114 trials sponsored, "Gynecologic Oncology Group" with 50 trials sponsored, "Radiation Therapy Oncology Group" with 41 trials sponsored and "Eastern Cooperative Oncology Group" with 41 trials sponsored. Other sponsors include 407 different institutions and companies that sponsored additional 150 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Abramson Cancer Center of the University of Pennsylvania" #1 collaborator was "National Cancer Institute (NCI)" with 350 trials as a collaborator, "Blood and Marrow Transplant Clinical Trials Network" with 23 trials as a collaborator, "NRG Oncology" with 23 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 18 trials as a collaborator and "National Marrow Donor Program" with 16 trials as a collaborator. Other collaborators include 231 different institutions and companies that were collaborators in the rest 109 trials.

According to Clinical.Site data, the most researched conditions in "Abramson Cancer Center of the University of Pennsylvania" are "Breast Cancer" (70 trials), "Brain and Central Nervous System Tumors" (33 trials), "Leukemia" (32 trials), "Ovarian Cancer" (32 trials) and "Head and Neck Cancer" (30 trials). Many other conditions were trialed in "Abramson Cancer Center of the University of Pennsylvania" in a lesser frequency.

Most popular intervention types in "Abramson Cancer Center of the University of Pennsylvania" are "Drug" (620 trials), "Other" (240 trials), "Biological" (201 trials), "Procedure" (180 trials) and "Radiation" (172 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (83 trials), "radiation therapy" (57 trials), "Quality-of-Life Assessment" (44 trials), "cisplatin" (41 trials) and "Paclitaxel" (40 trials). Other intervention names were less common.

The vast majority of trials in "Abramson Cancer Center of the University of Pennsylvania" are 738 trials for "All" genders, 154 trials for "Female" genders and 34 trials for "Male" genders.

Currently, there are 250 active trials in "Abramson Cancer Center of the University of Pennsylvania". 2 are not yet recruiting, 113 are recruiting, 129 are Active, not recruiting, and 6 are Enrolling by invitation. In total, there were 518 completed trials in Abramson Cancer Center of the University of Pennsylvania, 7 suspended trials, and 116 terminated clinical trials to date.

Out of the total trials that were conducted in Abramson Cancer Center of the University of Pennsylvania, 231 "Phase 1" clinical trials were conducted, 391 "Phase 2" clinical trials and 199 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 88 trials that are defined as “Not Applicable".